In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...

Background: Given the broad age range across which the quadrivalent meningococcal conjugate vaccine MenACWY-CRM is used, coadministration with routine vaccines should be evaluated across age ...

Birth in the U.S. before 1980 acceptable only for non-health science students Meningococcal conjugate quadrivalent (A,C,Y,W-135) (Menactra, Menveo or Nimenrix only) 1 dose; 1 dose MenACWY (formerly ...

As quadrivalent meningococcal conjugate vaccines offer the broadest, most durable and most effective protection, they are the preferred option over polysaccharide vaccines. However, conjugate ...

Travellers are advised to take the vaccination ten days before travelling in order to build immunity against the disease ...

The Advisory Committee on Immunization Practices approved immunization schedules for children and adolescents and for adults for 2025.

must receive the meningococcal (quadrivalent ACYW-135) vaccine at least 10 days before their trip. This vaccination is now compulsory and is part of broader efforts to prevent disease during the ...

and meningococcal serogroup B vaccines. Recommended influenza vaccines have been changed from the quadrivalent to the trivalent formulation. A. Patricia Wodi, M.D., also from the CDC, and ...